National Health Act 1953 - Amendment Special Arrangements under subsection 100(1) - Highly specialised drugs program (No. PB 73 of 2007)

Overview

The National Health Act 1953, enacted by the Parliament of Australia, serves as the legislative foundation for the Pharmaceutical Benefits Scheme (PBS). The PBS aims to ensure Australians have reliable, timely, and affordable access to a broad range of medicines. One of the key provisions of the Act, section 100, allows for special arrangements to be made to ensure an adequate supply of pharmaceutical products, particularly for those living in isolated areas or receiving treatment under circumstances where the standard PBS provisions are inadequate. The Highly Specialised Drugs Program, governed by these arrangements, is designed to ensure that highly specialised drugs are available to patients receiving treatment in private hospitals as non-admitted, day admitted, or discharge patients. The explanatory statement outlines amendments to the Highly Specialised Drugs Program, which were implemented to better cater to the needs of patients requiring treatment with highly specialised drugs, reflecting the policy objective of enhancing accessibility and adequacy of pharmaceutical benefits under specific medical conditions.

Scope and Application

The National Health Act 1953 governs the Pharmaceutical Benefits Scheme (PBS), through which the Commonwealth provides access to medicines for all Australians. The Act applies to all persons and entities within the Commonwealth's jurisdiction, particularly those involved in the provision and administration of pharmaceutical benefits. The Act's scope extends nationally, with the Pharmaceutical Benefits Advisory Committee (PBAC) playing a key role in recommending which drugs and medicinal preparations should be listed under the PBS. Certain drugs and preparations may be made available under special arrangements outlined in the Act, such as the Highly Specialised Drugs Program, which provides an adequate supply of special pharmaceutical products to persons in isolated areas or those receiving specific medical treatments. The Act allows the Minister to make, vary, or revoke these special arrangements. The Highly Specialised Drugs Program specifically targets individuals receiving treatment with highly specialised drugs at private hospitals, ensuring that these patients have access to necessary medications. This legislative instrument, which amends the previous arrangements made under the Act, came into effect on 1 October 2007, and includes changes such as allowing Infliximab to be prescribed for the treatment of patients with refractory Crohn’s disease.

Key Provisions

The key operative sections of the legislation (F2007L03624) focus on the Highly Specialised Drugs Program established under subsection 100(1)(b)(i) of the National Health Act 1953. This program aims to ensure that an adequate supply of special pharmaceutical products is available to individuals who are receiving medical treatment in circumstances where the Pharmaceutical Benefits Scheme (PBS) cannot efficiently or conveniently supply the necessary drugs. The Act allows the Minister to make arrangements for such special pharmaceutical products. Section 100(1) of the Act enables the Minister to create special arrangements for providing drugs to those living in isolated areas or receiving treatment where PBS benefits are inadequate or inefficient. Section 100(2) further empowers the Minister to vary or revoke these special arrangements. Section 100(3) stipulates that Part VII of the Act, which governs the PBS, operates subject to any special arrangements made under section 100(1). The Act imposes specific obligations on the parties involved, primarily the Minister for Health and Ageing, who is responsible for making and amending special arrangements under section 100. The Pharmaceutical Benefits Advisory Committee (PBAC), established under section 100A, plays a crucial role in recommending which drugs and medicinal preparations should be available as pharmaceutical benefits. This recommendation process is detailed under subsection 101(4) of the Act, which mandates that a drug or medicinal preparation cannot be declared under Part VII unless the PBAC has recommended it. Additionally, the Commonwealth/State Highly Specialised Drugs Working Party (HSDWP) makes recommendations to the PBAC regarding the suitability of certain drugs for listing under the Highly Specialised Drugs Program. The HSDWP considers funding and administrative aspects of supplying drugs through the hospital system. The legislation includes provisions for offences, penalties, and consequences for breaches, although the specific details of these are not explicitly stated in the provided text. Generally, breaches of provisions under the National Health Act 1953 can lead to both civil and criminal penalties. Civil penalties may include fines and other monetary sanctions, while criminal penalties could involve imprisonment or fines depending on the severity and nature of the breach. The maximum penalties are not detailed in the provided excerpt but would typically be outlined in the relevant sections of the Act or in associated regulations. Compliance with the Act is crucial to ensure the effective operation of the Highly Specialised Drugs Program and the broader PBS.